The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan

Antiviral Therapy

Volumn 5, Issue 1, 2000, Pages 41-48

  DeGruttola, Victor ^a   Dix, Lynn ^b   D'Aquila, Richard ^c   Holder, Dan ^d   Phillips, Andrew ^e   Ait Khaled, Mounir ^b   Baxter, John ^f   Clevenbergh, Philippe ^g   Hammer, Scott ^h   Harrigan, Richard ⁱ   Katzenstein, David ^j   Lanier, Randall ^b   Miller, Michael ^k   Para, Michael ^l   Yerly, Sabine ^m   Zolopa, Andrew ^j   Murray, Jeffrey ⁿ   Patick, Amy ^o   Miller, Veronica ^p   Castillo, Steven ^b   Pedneault, Louise ^b   Mellors, John ^q   more..

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b GLAXOSMITHKLINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^h New York Presbyterian Columbia University Medical Center   (United States)

ⁱ BC Center for Excellence in HIV/AIDS   (Canada)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Gilead Science   (United States)

^l THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^m GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁿ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^o AGOURON PHARMACEUTICALS INC   (United States)

^p GOETHE UNIVERSITY   (Germany)

^q UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

CLINICAL TRIAL; CONFERENCE PAPER; DATA ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTI-HIV AGENTS; CLINICAL TRIALS; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0344593433     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Ait-Khaled M, Falloon J, Rakik A, Griffin P, Thomas D, Myers R, Amphlett G, Tisdale M, and the CNA2007 Study Team. Baseline correlates of virological response to salvage therapy with efavirenz/abacavir/amprenavir in patients failing a PI-containing HAART. Antiviral Therapy 2000 (in press).
2. Baxter J, Mayers D, Wentworth D, Neaton J, Hoover M, Winters M, Mannheimer A, Thompson M, Abrams D, Brizz B, Ioannidis J, Merigan T, and the CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. Pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Antiviral Therapy 1999; 4 (Suppl. 1):43.
3. Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virological outcome. Journal of Infectious Diseases 1999; 179:1375-1381.
4. Durant J, Clevenbergh P, Hafon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999; 353:2195-2199.
5. Hammer S, Demeter L., DeGruttola V, Bassett R, Mellors J, Squires K, Fischl M, Hertogs K, Larder B, and the ACTG 372 Study Team. Relationship of phenotypic and genotypic resistance profiles to virological outcome in a trial of abacavir, nelfinavir, efavirenz, and adefovir dipivoxil in patients with virological failure receiving indinavir (ACTG 372). Antiviral Therapy 1999; 4 (Suppl. 1):45.